-

11:18:45 PM

CRSP Stock News

CRSP - CRISPR Therapeutics AG

10/14/21 7:00 AM

Nasdaq : CRSP

CRISPR Therapeutics Announces Transition of Chief Financial Officer

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer,

RHEA-AI

positive

10/12/21 4:01 PM

Nasdaq : CRSP

clinical trial

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at

RHEA-AI

neutral

10/05/21 4:05 PM

Nasdaq : CRSP

conferencesclinical trial

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,

RHEA-AI

neutral

10/01/21 8:00 AM

Nasdaq : CRSP

conferencesclinical trial

CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two poster presentations at the Society for Immunotherapy of

RHEA-AI

neutral

09/28/21 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

08/05/21 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

07/29/21 4:30 PM

Nasdaq : CRSP

earnings

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

- More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX130™ for the treatment of T-cell lymphoma- -Enrollment ongoing

RHEA-AI

positive

06/15/21 7:15 AM

Nasdaq : CRSP

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

CRISPR Therapeutics (Nasdaq: CRSP), a

RHEA-AI

positive

06/11/21 3:05 AM

Nasdaq : VRTX, CRSP

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a

RHEA-AI

neutral

05/25/21 8:00 AM

Nasdaq : CRSP

conferences

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

RHEA-AI

neutral

CRSP Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitecrisprtx.com
CeoSamarth Kulkarni
Security nameCRISPR Therapeutics AG
Issue typecs
SectorManufacturing
Sic code2836
Employees410
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressBaarerstrasse 14
StateZug
CityZug
Zip6300
CountrySwitzerland
Phone41415613277

CRSP Description:

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.